Duloxetine Aristo 60 mg Norwegen - Norwegisch - Statens legemiddelverk

duloxetine aristo 60 mg

aristo pharma gmbh - duloksetinhydroklorid - enterokapsel, hard - 60 mg

Duloxetine Aristo 30 mg Norwegen - Norwegisch - Statens legemiddelverk

duloxetine aristo 30 mg

aristo pharma gmbh - duloksetinhydroklorid - enterokapsel, hard - 30 mg

Viant Norwegen - Norwegisch - Statens legemiddelverk

viant

b. braun melsungen ag - tokoferol, helracemisk, a- / askorbinsyre / biotin / kolekalsiferol / cyanokobalamin / dekspantenol / folsyre / nikotinamid / fytomenadion / pyridoksinhydroklorid / retinylpalmitat / riboflavinnatriumfosfathydrat / tiaminhydroklorid - pulver til infusjonsvæske, oppløsning

Abilify 1 mg/ ml Norwegen - Norwegisch - Statens legemiddelverk

abilify 1 mg/ ml

2care4 aps - aripiprazol - mikstur, oppløsning - 1 mg/ ml

Apixaban Accord Europäische Union - Norwegisch - EMA (European Medicines Agency)

apixaban accord

accord healthcare s.l.u. - apixaban - venous thromboembolism; stroke; arthroplasty - antithrombotic agents - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery. forebygging av slag og systemisk emboli hos voksne pasienter med ikke-valvulær atrieflimmer (nvaf), med én eller flere risikofaktorer, slik som tidligere hjerneslag eller forbigående ischaemic angrep (tia); alder ≥ 75 år, hypertensjon; diabetes mellitus; symptomatisk hjertesvikt (nyha klasse ≥ ii). behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne (se kapittel 4. 4 for haemodynamically ustabil pe pasienter). prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii). behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne (se kapittel 4. 4 for haemodynamically ustabil pe pasienter).

Cymbalta 30 mg Norwegen - Norwegisch - Statens legemiddelverk

cymbalta 30 mg

2care4 aps - duloksetinhydroklorid - enterokapsel, hard - 30 mg

Cymbalta 60 mg Norwegen - Norwegisch - Statens legemiddelverk

cymbalta 60 mg

2care4 aps - duloksetinhydroklorid - enterokapsel, hard - 60 mg

Retsevmo Europäische Union - Norwegisch - EMA (European Medicines Agency)

retsevmo

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiske midler - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Rukobia Europäische Union - Norwegisch - EMA (European Medicines Agency)

rukobia

viiv healthcare b.v. - fostemsavir trometamol - hiv-infeksjoner - antivirale midler til systemisk bruk - rukobia, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant hiv-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Lumoxiti Europäische Union - Norwegisch - EMA (European Medicines Agency)

lumoxiti

astrazeneca ab - moxetumomab pasudotox - leukemi, hårete celler - antineoplastiske midler - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).